Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Nicola G Ghazi1, Christopher S Ketcherside1, Jason Sheehan2, Brian P Conway1
1Department of Ophthalmology and 2Neurosurgery, University of Virginia Health System, Charlottesville, VA, USA
Purpose: To report outcomes of Gamma Knife radiosurgery (GKRS) in treating uveal melanoma lesions ineligible for standard brachytherapy.
Methods: A retrospective interventional case series of uveal melanoma patients treated with GKRS between 1996 and 2004 was performed. The main outcome measures were local tumor control, metastasis, and death.
Results: Four patients with uveal melanoma treated with GKS were identified. Three tumors involved the ciliary body and one was macular with its border within 2 mm of the optic disc. Adequate globe stabilization was achieved by retrobulbar anesthesia in all cases. Pretreatment mean visual acuity was 20/30. Tumor volume as determined by magnetic resonance imaging ranged from 0.05 to 0.30 cc. Ultrasonographic greatest tumor diameter and height ranged from 11 to 18 mm (mean 14.5 mm) and 2.9 to 4.5 mm (mean 3.6 mm), respectively. The peripheral dose varied from 16.5 to 30 Gray. Local tumor control was achieved in all cases over a follow up period of 6 to 96 months. Mean final visual acuity was 20/50. One eye was enucleated for neovascular glaucoma and one patient died from liver and lung metastasis.
Conclusions: GKRS for uveal melanoma appears to be safe and effective. The metastasis and mortality rates appear to be comparable to those following brachytherapy and enucleation. Moreover, local tumor control and enucleation rates are similar to those following brachytherapy. The findings in this small series suggest a role for GKRS in the treatment of selected cases of uveal melanomas.
Keywords: gamma knife radiosurgery, radiation therapy, uveal melanoma
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other article by this author:
Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization?
Nicola G Ghazi, Brian P Conway, James S Tiedeman, Steven J Yoon
Published Date: 18 September 2008
Readers of this article also read:
Wong AWY, Zhang C, Chu CH
Published Date: 8 May 2014
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Published Date: 27 March 2014
Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T
Published Date: 19 March 2014
Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H
Published Date: 4 March 2014
Gao B, Doan A, Hybertson BM
Published Date: 3 February 2014
Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG
Published Date: 6 March 2012
Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease
Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L
Published Date: 6 September 2011
Published Date: 18 August 2011
Hatem A Jlala, Nigel M Bedforth, Jonathan G Hardman
Published Date: 12 August 2010
A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar
Published Date: 4 February 2009